Navigation Links
Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Updates LGND Research Report with New Material Information
Date:8/4/2014

MARLBOROUGH, Mass., Aug. 4, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals (NASDAQ: LGND) and updated with new information its June 16 and July 3, 2014 research reports on the stock.

  • Lemelson Capital's original June 16, 2014 report can be found here.
  • Lemelson Capital's appended 12-paged update, published on July 3, 2014, can be found here.

"Ligand's 76 percent plunge in EPS, reported in the company's Q2 earnings release this morning, is alarming, while the negative impact of new oral regimens on interferon use and, parenthetically, Promacta sales have not yet hit the P & L of Ligand or its partner Amgen," Lemelson Capital Management's Chief Investment Officer Emmanuel Lemelson said in releasing today's updated Ligand Pharmaceuticals report.  "Key revenue programs such as collaborative research and development are also continuing their multi-year slide, while stock-based compensation has reached new highs, far in excess of the company's insipid earnings," he said.

Today's updated research report on Ligand Pharmaceuticals includes new material information that has been added to the firm's original June 16, 2014 research report. Today's report can be found here.

Disclosure: Lemelson Capital is currently short shares of LGND for its clients.

About Lemelson Capital Management:

Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments.  The firm's flagship fund, The Amvona Fund, has been named repeatedly one of the world's top performing hedge funds.  For more information, see:  http://www.lemelsoncapital.com

Contact:
+Emmanuel Lemelson
Chief Investment Officer
Lemelson Capital Management, LLC
(508) 630-2281


'/>"/>
SOURCE Lemelson Capital Management, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. PLC Systems Secures Additional Financing For US Clinical Trials And General Working Capital
2. Genstar Capital Completes ERT Acquisition In A Take-Private Transaction
3. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
4. Intrepid Investment Bankers LLC Advises A-Med Health Care in the Sale of its Specialty Pharmacy Assets to Modern HC Pharmacy, Inc., a portfolio company of Altamont Capital Partners
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Physicians Capital Investments, Physicians Capital Markets, and EDGE Realty Capital Markets announce a new strategic initiative
7. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
8. Innophos To Present At 2012 KeyBanc Capital Markets Basic Materials & Packaging Conference
9. GP Strategies to Present at the BMO Capital Markets 12th Annual Back to School Education Conference
10. Raging Capital Calls On Taro Pharmaceutical Shareholders To Vote Against The Taro / Sun Pharma Merger
11. Masimo to Present at Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
(Date:4/27/2016)... 27, 2016   Zillion Group today ... technology platform, which specializes in live video consultation. ... digital products, Zillion enables companies to realize the ... to take control of their health. ... – including one-to-one, group and webcast scheduled or ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... of our nation’s productivity, stability, even security. Most importantly, employees are the single ... Then why are American workers so unhappy? , Just under half of American ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global ... Park on Sunday, with sunny skies, a light breeze and temperatures in the 60s. ... , The 5k Run and Walk and 1-mile walk were held to increase ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... of patented products, announces the Gyrociser, an exercise invention which aids in proper ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
Breaking Medicine News(10 mins):